Emerging role of interleukin-33 in autoimmune diseases

Immunology

Volumn 141, Issue 1, 2014, Pages 9-17

  Pei, Cheng ^a,b   Barbour, Mark ^a   Fairlie Clarke, Karen J ^a   Allan, Debbie ^a   Mu, Rong ^c   Jiang, Hui Rong ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Autoimmune diseases; Inflammation; Interleukin 33; ST2

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 33; INTERLEUKIN 5;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; BEHCET DISEASE; CROHN DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; EPITHELIUM HYPERPLASIA; FIBROBLAST; GENETIC VARIABILITY; GLIA CELL; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; JOINT DESTRUCTION; LYMPH NODE CELL; MAST CELL; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ULCERATIVE COLITIS;

AUTOIMMUNE DISEASES; INFLAMMATION; INTERLEUKIN-33; ST2;

ANIMALS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKINS;

EID: 84889653647     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12174     Document Type: Article

References (95)

1. Baekkevold ES, Roussigne M, Yamanaka T et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003; 163:69-79.
2. Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479-90.
3. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 2009; 106:9021-6.
4. Luthi AU, Cullen SP, McNeela EA et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009; 31:84-98.
5. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10:103-10.
6. Kakkar R, Hei H, Dobner S, Lee RT. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012; 287:6941-8.
7. Mirchandani AS, Salmond RJ, Liew FY. Interleukin-33 and the function of innate lymphoid cells. Trends Immunol 2012; 33:389-96.
8. Ohno T, Oboki K, Kajiwara N et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol 2009; 183:7890-7.
9. Talabot-Ayer D, Calo N, Vigne S, Lamacchia C, Gabay C, Palmer G. The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters. J Leukoc Biol 2012; 91:119-25.
10. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 2007; 104:282-7.
11. Roussel L, Erard M, Cayrol C, Girard J-P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 2008; 9:1006-12.
12. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, Martin MU. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol 2011; 187:1609-16.
13. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A 2007; 104:18660-5.
14. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007; 179:2051-4.
15. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008; 20:1019-30.
16. Bonilla WV, Frohlich A, Senn K et al. The alarmin interleukin-33 drives protective antiviral CD8 T cell responses. Science 2012; 335:984-9.
17. Besnard AG, Togbe D, Guillou N, Erard F, Quesniaux V, Ryffel B. IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur J Immunol 2011; 41:1675-86.
18. Barlow JL, Peel S, Fox J et al. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J Allergy Clin Immunol 2013; 132:933-41.
19. Komai-Koma M, Gilchrist DS, McKenzie ANJ, Goodyear CS, Xu D, Liew FY. IL-33 activates B1 cells and exacerbates contact sensitivity. J Immunol 2011; 186:2584-91.
20. + T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008; 181:4780-90.
21. Kurowska-Stolarska M, Stolarski B, Kewin P et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009; 183:6469-77.
22. Silver MR, Margulis A, Wood N, Goldman SJ, Kasaian M, Chaudhary D. IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res 2010; 59:207-18.
23. Jung MY, Smrz D, Desai A et al. IL-33 induces a hyporesponsive phenotype in human and mouse mast cells. J Immunol 2013; 190:531-8.
24. Aoki S, Hayakawa M, Ozaki H, Takezako N, Obata H, Ibaraki N, Tsuru T, Tominaga S, Yanagisawa K. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem 2010; 335:75-81.
25. Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H, Kim J, Kim YM, Kwon YG. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009; 114:3117-26.
26. Matsuda A, Okayama Y, Terai N et al. The role of interleukin-33 in chronic allergic conjunctivitis. Invest Ophthalmol Vis Sci 2009; 50:4646-52.
27. Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol 2010; 185:3472-80.
28. Lloyd CM. IL-33 family members and asthma - bridging innate and adaptive immune responses. Curr Opin Immunol 2010; 22:800-6.
29. Kondo Y, Yoshimoto T, Yasuda K et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008; 20:791-800.
30. Ohno T, Morita H, Arae K, Matsumoto K, Nakae S. Interleukin-33 in allergy. Allergy 2012; 67:1203-14.
31. Borish L, Steinke JW. Interleukin-33 in asthma: how big of a role does it play? Curr Allergy Asthma Rep 2011; 11:7-11.
32. Salmond RJ, Mirchandani AS, Besnard A-G, Bain CC, Thomson NC, Liew FY. IL-33 induces innate lymphoid cell-mediated airway inflammation by activating mammalian target of rapamycin. J Allergy Clin Immunol 2012; 130(1159-66):e6.
33. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 2008; 180:2443-9.
34. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008; 7:827-40.
35. Miller AM, Xu D, Asquith DL et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205:339-46.
36. Miller AM, Liew FY. The IL-33/ST2 pathway - a new therapeutic target in cardiovascular disease. Pharmacol Ther 2011; 131:179-86.
37. Verri WA Jr, Guerrero AT, Fukada SY et al. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci U S A 2008; 105:2723-8.
38. Xu D, Jiang HR, Kewin P et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A 2008; 105:10913-8.
39. Palmer G, Talabot-Ayer D, Lamacchia C et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009; 60:738-49.
40. Xiangyang Z, Lutian Y, Lin Z, Liping X, Hui S, Jing L. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine 2012; 58:6-9.
41. Hong YS, Moon SJ, Joo YB et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011; 26:1132-9.
42. Matsuyama Y, Okazaki H, Hoshino M et al. Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1β signaling and a poor clinical response. Rheumatol Int 2012; 32:1397-401.
43. Talabot-Ayer D, McKee T, Gindre P, Bas S, Baeten DL, Gabay C, Palmer G. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 2012; 79:32-7.
44. Matsuyama Y, Okazaki H, Tamemoto H et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010; 37:18-25.
45. Schulze J, Bickert T, Beil FT et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res 2011; 26:704-17.
46. Mu R, Huang HQ, Li YH, Li C, Ye H, Li ZG. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J Rheumatol 2010; 37:2006-13.
47. Kageyama Y, Torikai E, Tsujimura K, Kobayashi M. Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33. Mod Rheumatol 2012; 22:89-93.
48. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004; 173:145-50.
49. Xu D, Jiang HR, Li Y et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol 2010; 184:2620-6.
50. Martin P, Talabot-Ayer D, Seemayer CA et al. Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis Res Ther 2013; 15:R13.
51. Keller J, Catala-Lehnen P, Wintges K et al. Transgenic over-expression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochem Biophys Res Commun 2012; 417:217-22.
52. Chapuis J, Hot D, Hansmannel F et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry 2009; 14:1004-16.
53. Yu JT, Song JH, Wang ND et al. Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer's disease. Neurobiol Aging 2012; 33:1014.e11-4.
54. Hudson CA, Christophi GP, Gruber RC, Wilmore JR, Lawrence DA, Massa PT. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 2008; 84:631-43.
55. Jiang HR, Milovanovic M, Allan D et al. IL-33 attenuates experimental autoimmune encephalomyelitis by suppressing IL-17 and IFN-γ production and inducing alternatively-activated macrophages. Eur J Immunol 2012; 42:1804-14.
56. Yasuoka S, Kawanokuchi J, Parajuli B et al. Production and functions of IL-33 in the central nervous system. Brain Res 2011; 1385:8-17.
57. Christophi GP, Gruber RC, Panos M, Christophi RL, Jubelt B, Massa PT. Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin Immunol 2012; 142:308-19.
58. Li M, Li Y, Liu X, Gao X, Wang Y. IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuroimmunol 2012; 247:25-31.
59. Oboki K, Ohno T, Kajiwara N et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 2010; 107:18581-6.
60. Miller AM, Asquith DL, Hueber AJ et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res 2010; 107:650-8.
61. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, Lukic ML. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 2012; 52:89-99.
62. Milovanovic M, Volarevic V, Ljujic B, Radosavljevic G, Jovanovic I, Arsenijevic N, Lukic ML. Deletion of IL-33R (ST2) abrogates resistance to EAE in BALB/C mice by enhancing polarization of APC to inflammatory phenotype. PLoS ONE 2012; 7:e45225.
63. Latiano A, Palmieri O, Pastorelli L et al. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS ONE 2013; 8:e62144.
64. Seidelin JB, Bjerrum JT, Coskun M, Widjaya B, Vainer B, Nielsen OH. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett 2010; 128:80-5.
65. Beltran CJ, Nunez LE, Diaz-Jimenez D et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16:1097-107.
66. Pastorelli L, Garg RR, Hoang SB et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A 2010; 107:8017-22.
67. Ajdukovic J, Tonkic A, Salamunic I, Hozo I, Simunic M, Bonacin D. Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative colitis. Hepatogastroenterology 2010; 57:1442-4.
68. Diaz-Jimenez D, Nunez LE, Beltran CJ et al. Soluble ST2: a new and promising activity marker in ulcerative colitis. World J Gastroenterol 2011; 17:2181-90.
69. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157:1261-70.
70. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009; 58:1152-67.
71. Liew FY. IL-33: a Janus cytokine. Ann Rheum Dis 2012; 71(Suppl. 2):i101-4.
72. Duan L, Chen J, Zhang H et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3 regulatory T-cell responses in mice. Mol Med 2012; 18:753-61.
73. Grobeta P, Doser K, Falk W, Obermeier F, Hofmann C. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis 2012; 18:1900-9.
74. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369:1627-40.
75. Sponheim J, Pollheimer J, Olsen T et al. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol 2010; 177:2804-15.
76. Lopetuso LR, Scaldaferri F, Pizarro TT. Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair 2012; 5:18.
77. Ouziel R, Gustot T, Moreno C et al. The ST2 pathway is involved in acute pancreatitis: a translational study in humans and mice. Am J Pathol 2012; 180:2330-9.
78. Masamune A, Watanabe T, Kikuta K, Satoh K, Kanno A, Shimosegawa T. Nuclear expression of interleukin-33 in pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2010; 299:G821-32.
79. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm 2011; 8:22.
80. Fousteris E, Melidonis A, Panoutsopoulos G et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc Diabetol 2011; 10:101.
81. Miller AM, Purves D, McConnachie A et al. Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS ONE 2012; 7:e47830.
82. Zdravkovic N, Shahin A, Arsenijevic N, Lukic ML, Mensah-Brown EP. Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin. Mol Immunol 2009; 47:28-36.
83. Rui T, Zhang J, Xu X, Yao Y, Kao R, Martin CM. Reduction in IL-33 expression exaggerates ischaemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. Cardiovasc Res 2012; 94:370-8.
84. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 2001; 284:1104-8.
85. Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan EY, Lam KF, Xu D. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2010; 49:520-7.
86. Yang Z, Liang Y, Xi W, Li C, Zhong R. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin Exp Med 2011; 11:75-80.
87. Manetti M, Ibba-Manneschi L, Liakouli V et al. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 2010; 69:598-605.
88. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 2011; 30:825-30.
89. Terras S, Opitz E, Moritz RK, Hoxtermann S, Gambichler T, Kreuter A. Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis. Ann Rheum Dis 2012; 72:144-5.
90. Rankin AL, Mumm JB, Murphy E et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 2010; 184:1526-35.
91. Savinko T, Matikainen S, Saarialho-Kere U et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol 2012; 132:1392-400.
92. Alase A, Seltmann J, Werfel T, Wittmann M. Interleukin-33 modulates the expression of human β-defensin 2 in human primary keratinocytes and may influence the susceptibility to bacterial superinfection in acute atopic dermatitis. Br J Dermatol 2012; 167:1386-9.
93. Han GW, Zeng LW, Liang CX, Cheng BL, Yu BS, Li HM, Zeng FF, Liu SY. Serum levels of IL-33 is increased in patients with ankylosing spondylitis. Clin Rheumatol 2011; 30:1583-8.
94. Lin CY, Pfluger CM, Henderson RD, McCombe PA. Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis. J Neuroimmunol 2012; 249:93-5.
95. Hamzaoui K, Kaabachi W, Fazaa B, Zakraoui L, Mili Boussen I, Haj Sassi F. Serum IL-33 levels and skin mRNA expression in Behcet's disease. Clin Exp Rheumatol 2013; 31(Suppl. 77):6-14.